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Burkholderia cenocepacia, an opportunistic respiratory pathogen particularly relevant for cystic 
fibrosis patients, is difficult to eradicate due to its high level of resistance to most clinically relevant 
antimicrobials. Consequently, the discovery of new antimicrobials as well as molecules capable of 
inhibiting its virulence is mandatory. In this regard quorum sensing (QS) represents a good target for 
anti-virulence therapies, as it has been linked to biofilm formation and is important for the production 
of several virulence factors, including proteases and siderophores. Here, we report the discovery of new 
diketopiperazine inhibitors of the B. cenocepacia acyl homoserine lactone synthase CepI, and report 
their anti-virulence properties. Out of ten different compounds assayed against recombinant CepI, 
four were effective inhibitors, with IC50 values in the micromolar range. The best compounds interfered 
with protease and siderophore production, as well as with biofilm formation, and showed good in vivo 
activity in a Caenorhabditis elegans infection model. These molecules were also tested in human cells 
and showed very low toxicity. Therefore, they could be considered for in vivo combined treatments 
with established or novel antimicrobials, to improve the current therapeutic strategies against B. 
cenocepacia.
Cystic Fibrosis (CF) is an autosomal recessive disease affecting approximately 100,000 people worldwide, and 
is considered a rare disease1. The genetic defect causes the malfunction of the chloride channel termed Cystic 
Fibrosis Transmembrane conductance Regulator (CFTR), which leads to formation and build-up of sticky mucus. 
This results in impairment of mucociliary clearance of opportunistic pathogens, making the control of infections 
a major concern2,3.
Burkholderia cenocepacia, a member of the Burkholderia cepacia complex (Bcc), is one of these opportunistic 
pathogens. Infection with B. cenocepacia is often associated with poor clinical outcome and high mortality 
resulting from a decline of lung function leading to fatal pneumonia4,5. These bacteria are intrinsically multidrug 
resistant and can form biofilms in the airways, thus increasing their tolerance to high concentrations of drugs6,7. 
Consequently, innovative solutions are needed to improve the effectiveness of current antibacterial therapies.
Quorum sensing (QS) is an intercellular cell density dependent communication process, based on the synthesis 
and secretion of signal molecules8. These molecules are sensed by bacteria through specific receptors, which in 
turn mediate the induction and/or the repression of target genes in relation to the signal molecule concentration. 
The involvement of QS in biofilm formation and expression of other major virulence factors such as proteases, 
siderophores, and toxins is well-established9,10, and the Burkholderia QS system is an interesting candidate drug 
target11,12.
The hypothesis is that interfering with the activity of signal molecule synthases renders the bacteria unable 
to produce virulence factors and thus less able to colonize the host. Furthermore, therapies directed at inhibiting 
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QS (as well as other anti-virulence treatments) do not directly kill the bacteria, making the development of drug 
resistance less likely. Finally, these QS anti-virulence drugs might be used in combination with established or 
novel antimicrobials so as to improve the currently available therapies11.
All Burkholderia species encode at least one QS system consisting of an Acyl Homoserine Lactone (AHL) 
synthase and an AHL receptor13. B. cenocepacia J2315 possesses two complete AHL QS systems (CepIR and 
CciIR) and one orphan (a gene encoding a regulator not paired up with a synthase, CepR2) plus the Burkholderia 
Diffusible Signal Factor (BDSF)-based system, RpfFBC14–16.
CepI is responsible for the synthesis of N-octanoyl-homoserine lactone (C8-HSL) and, in smaller amounts, of 
N-hexanoyl-homoserine lactone (C6-HSL) starting from acylated acyl-carrier protein (acyl-ACP) and S-adenosyl 
methionine (SAM) (Fig. 1)17.
In a previous study, the properties of various B. cenocepacia mutants affected in QS were characterized18. Our 
results confirmed the involvement of CepI in biofilm formation, protease production and virulence. Moreover, 
those results highlighted the interplay among the AHL and BDSF-based systems, suggesting that the BDSF sys-
tem controls the AHL-based QS system18.
In the present study, CepI from B. cenocepacia J2315 was characterized by using structural bioinformatics and 
by heterologous production and purification in Escherichia coli. An enzymatic assay was set up (based on previous 
work19) and was shown to be suitable for high-throughput screening of compounds targeting CepI.
To this end, ten new molecules were synthesized based on the diketopiperazines scaffold (diketopiperazines 
were previously described as QS inhibitors20). The molecules were tested for inhibitory activity against CepI. Four 
of these compounds interfered with CepI activity in a dose-dependent manner. Further testing highlighted that 
these inhibitors also impaired the ability of B. cenocepacia J2315 to produce proteases, siderophores, and to form 
biofilms in vitro. Moreover, the administration of the compounds increased survival of Caenorhabditis elegans 
nematodes infected with B. cenocepacia J2315, suggesting that the virulence of the strain was also attenuated 
under in vivo conditions.
Results
CepI enzymatic activity is inhibited by four diketopiperazine derivatives. In order to identify 
molecules able to inhibit the QS enzyme CepI, the recombinant protein was purified (Supplementary Fig. S1), 
characterized (Supplementary Fig. S2) and used to test a series of new compounds (Fig. 2). The purified recombi-
nant CepI was catalytically active, showing steady state kinetic parameters towards C8-ACP very similar to those 
of other AHL synthases19,21 (Supplementary Fig. S2). Moreover, the protein was rather stable in 50 mM TrisHCl 
pH 8.0, 150 mM NaCl, 1 mM DTT, 10% glycerol and it may be stored in these conditions at − 80 °C for over 1 year 
without significant loss of activity. Then the sample can be kept at 4 °C for maximum 1 week (data not shown). 
Initially, the efficacy of compound 1 from Christensen et al. (3-(4-methylpiperazin-1-yl)(pyridin-2-yl)methyl]-
2-phenyl-1H-indol-1-ol) was tested, as it has been demonstrated to be very active against the Burkholderia mallei 
Figure 1. CepI catalyzed formation of homoserine lactone. The two substrates octanoyl-acyl carrier protein 
(ACP) and S-adenosylmethionine (SAM) form an acyl-SAM intermediate with the releasing of the holo-ACP. 
The subsequent lactonization gives rise to 5′ -methylthioadenosine and the signal molecule octanoyl homoserine 
lactone.
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AHL-synthase19. The compound was also found to be effective against the B. cenocepacia CepI (IC50: 7.2± 0.2 μ M), 
thus confirming that the recombinant enzyme is suitable for inhibitor screening.
For this purpose, ten novel diketopiperazines were synthetized (Fig. 2) based on the structure of diketopiper-
azines which act as QS inhibitors20. A redox moiety was introduced in the molecule using the quinone function 
and the corresponding quinones and hydroquinones were synthesized. Four of these newly synthesized com-
pounds (8a, 8b, 8c, and to a lesser extent 6a), were effective inhibitors of the CepI enzymatic activity, with IC50 
values ranging from 5 to 30 μ M (Supplementary Table S1, Fig. 3A).
To better characterize the mechanism of action of this newly synthesized class of CepI inhibitors, the appar-
ent inhibition constants of the most active compound (8b) were determined. The compound behaved as a 
non-competitive inhibitor towards both C8-ACP and SAM substrates, showing an apparent Ki value of 17± 0.6 μ M 
(Fig. 3B,C), proving to be very active in inhibiting CepI in vitro.
In order to determine structure-activity relationship of the inhibitors, we wanted to determine the structure 
of CepI. However, despite numerous trials, the enzyme proved to be recalcitrant to crystallization. Therefore, we 
performed extensive structural bioinformatics predictions through comparative evaluation of multiple struc-
tural prediction and docking algorithms, as described in the Supplementary Materials and Methods. The high 
sequence conservation among homologous AHL synthases of known three-dimensional structure such as TofI22, 
EsaI23, LasI24 and CepI (Supplementary Table S2, Supplementary Fig. S3), as well as the broad structural fold 
conservation with other prokaryotic and eukaryotic acyltransferase homologs allowed clear identification of the 
amino acid residues involved in substrate recognition and catalysis (Supplementary Fig. S4). Overall, CepI shares 
the structural architecture of homologous AHL synthases25, characterized by a broad, V-shaped substrate binding 
Figure 2. Chemical structure of diketopiperazines investigated in this work. 
Figure 3. Inhibition of CepI activity. (A) IC50 determination of 6a (○ ), 8a(◇), 8b (▿ ) and 8c (◽ ) against 
CepI. IC50 values were determined by fitting the experimental data, as reported in Materials and Methods. 
(B) Reciprocal plot of the steady state kinetic analysis towards SAM of CepI, in the presence of different 
concentrations of 8b (⦁ 0 mM; ▾ 0.01 mM; ◾ 0.02 mM; ◆ 0.05 mM; ▴ 0.1 mM). (C) Reciprocal plot of the steady 
state kinetic analysis towards C8-ACP of CepI in the presence of different concentrations of 8b (⦁ 0 mM; ▾ 
0.01 mM; ◾ 0.02 mM; ◆ 0.05 mM).
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pocket that crosses the entire enzyme fold and shows very high sequence conservation (Supplementary Fig. S4). 
Previously reported mutagenesis studies on CepI homologs identified the critical amino acid residues impli-
cated in synthase enzymatic activity25–27. Sequence alignments and comparison of our CepI homology model 
with available crystal structures shows complete conservation of all residues essential for enzymatic activity 
(Supplementary Fig. S3). Residues Phe27, Trp33 and Arg104 are likely implicated in stabilization of the both 
substrates23,25, whereas residues Asp45, Glu101 and Ser103, fully conserved in all AHL synthases, have been 
implicated in catalysis22,23,25. A broad region spanning from residue 90 to 180 shapes a shallow hydrophobic tun-
nel, likely responsible for hosting the acyl moiety of the C8-ACP substrate during catalysis. Of note, all residues 
lining this putative acyl-binding pocket are conserved between CepI and TofI (Supplementary Fig. S3); both CepI 
and TofI synthesize C8-AHL. The C-terminus is characterized by the highest sequence heterogeneity among 
homologous enzymes. Nevertheless, multiple solvent-exposed positively charged residues, including Arg150, 
Arg154, and Arg161, implicated in the recognition of the negatively charged C-terminus of the ACP carrier and 
therefore essential for productive substrate binding24, are conserved (Supplementary Fig. S3).
Attempts to identify the putative binding site of compound 8b to the CepI structural model using molecular 
docking consistently showed the presence of multiple high-affinity contact sites spread around the CepI structure 
(Supplementary Fig. S5). Interestingly, all putative interaction sites identified by docking were outside of the SAM 
and acyl substrate binding site, supporting the biochemical evidence for non-competitive inhibition. Among 
these, putative binding sites with predicted strong stabilization energies were found proximate to the loop cover-
ing residues 33–47, critical for SAM stabilization in TofI22, and near the Arg residues involved in interaction with 
ACP (Supplementary Fig. S5).
Quorum sensing inhibitor (QSI) MIC in planktonic cells. 1 to 128 μ g/ml of the compounds 6a, 6b, 6c, 
7a, 7b, 7c, 8a, 8b, 8c, and 9 were added to planktonic B. cenocepacia J2315 cells. B. cenocepacia was able to grow 
even at the highest concentration tested, demonstrating that the compounds did not show any bactericidal or 
bacteriostatic activity (Supplementary Table S1, Supplementary Methods).
To determine synergy, 20 μ g/ml of 6a or 8b was combined with two-fold dilutions of ampicillin, aztreonam, 
ceftazidime, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, levofloxacin, meropenem, nalidixic 
acid, norfloxacin, sparfloxacin, streptomycin, tetracycline, tobramycin, or trimethoprim (See Supplementary 
Methods).
Neither compound altered the susceptibility of B. cenocepacia toward the antibiotics tested. In fact, the frac-
tional inhibitory concentration (FIC) indices were > 0.5 for all combinations, indicating that no synergistic activ-
ity occurred and that the interactions observed were indifferent (data not shown).
QSIs affect the in vitro production of proteases and siderophores in B. cenocepacia. We sub-
sequently evaluated the effect of 6a and 8b on the production of putative virulence factors. It was previously 
shown that the protease production in B. cenocepacia is controlled by AHL-based signaling28,29. In B. cenocepacia 
J2315 the protease activity decreased significantly (p < 0.05) in the presence of increasing concentrations of the 
two compounds (1–100 μ M) (Fig. 4A). More precisely, compound 8b induced a dose-dependent decrease in the 
production of proteases of 12–38% respect to the cells treated with the solvent DMSO, while the compound 6a 
led to a decrease of 16–46%.
To assess if siderophore production was influenced by the two inhibitors, four different concentrations of 8b 
and 6a were tested (1, 10, 25 and 100 μ M) with cells grown on CAS agar medium in the presence of low iron con-
centrations. On these plates, siderophores remove iron from the CAS dye complex, resulting in a blue-to-orange 
Figure 4. Protease and siderophore production in the presence of QS inhibitors. (A) Percentage of protease 
activity in the presence of compounds 6a (light grey bars) or 8b (black bars) compared to the treatment with 
DMSO (white bar). (B) Siderophore production in the presence of DMSO (white bars, p > 0.4), 6a (light grey 
bars) and 8b (black bars) compared to the untreated cells (NT, dark grey bar). *p < 0.05; **p < 0.01.
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color change around the colonies30. Both compounds were able to decrease siderophore production in 
B. cenocepacia J2315 by 25–42% and 13–69%, respectively (p < 0.05) (Fig. 4B).
Effect of QSIs on biofilm formation. In order to assess the effect of compounds 6a and 8b on bio-
film morphology, we evaluated biofilm formation in the presence or absence of the compounds. While in the 
untreated controls (i.e. biofilm treated with solvent control) the morphological variation of the biofilm was minor, 
significant morphological differences were observed for the treated biofilms.
B. cenocepacia J2315 biofilms formed in the absence of compounds were able to almost completely cover the 
surface of the well (Fig. 5). In contrast, biofilms formed in the presence of 10 μ M, 25 μ M and 100 μ M of 6a and 
8b were less structured, contained fewer cells and were unable to colonize the entire surface of the well (Fig. 5). 
Furthermore, minor differences were also observed between untreated control biofilm and those treated with 1 μ M 
of 6a and 8b, suggesting that 6a and 8b affect biofilm formation even at very low concentrations. However, we also 
observed minor variations in biofilm morphology in the solvent-treated controls, and it remains to be determined 
whether the minor differences observed at low inhibitor concentrations are biologically relevant.
Effect of QSIs on survival of C. elegans infected by B. cenocepacia. C. elegans infected with 
B. cenocepacia J2315 was used to evaluate the ability of the compounds to protect against infection18,31. The com-
pounds themselves did not display any toxic effect against C. elegans nematodes, since no significant differences 
in survival were observed after 24 h and 48 h in uninfected C. elegans treated with the compounds in concen-
trations ranging between 1–25 μ M (Table 1). In contrast, survival was significantly decreased when infected 
C. elegans received no treatment (survival of 65% ± 7% and 35% ± 18% after 24 h and 48 h, respectively compared 
to 96% ± 5% and 95% ± 5% survival for uninfected untreated nematodes) (Table 1). Both 6a and 8b significantly 
protected C. elegans nematodes against infection with B. cenocepacia J2315 (Table 1). Similar levels of survival 
Figure 5. Representative microscopic images of B. cenocepacia J2315 biofilms. Biofilms formed in the 
absence (CTRL, i.e. solvent control) or presence of different concentrations of 6a (A) or 8b (B).
Compound Concentration (μM)
C. elegans survival (%)
24 h 48 h
No infection B. cenocepacia J2315 No infection B. cenocepacia J2315
CTRL — 96 ± 5 65 ± 7 95 ± 5 35 ± 18
6a 1 98 ± 6 73 ± 10* 91 ± 12 56 ± 11*
5 99 ± 2 86 ± 6* 98 ± 4 66 ± 5*
10 91 ± 8 88 ± 17* 86 ± 10 74 ± 11*
25 91 ± 4 91 ± 9* 91 ± 6 82 ± 5*
8b 1 98 ± 5 84 ± 2* 97 ± 6 50 ± 6*
5 97 ± 7 89 ± 4* 95 ± 7 55 ± 9*
10 99 ± 2 93 ± 7* 95 ± 10 70 ± 7*
25 98 ± 5 91 ± 5* 96 ± 5 75 ± 3*
Table 1.  Percent survival of uninfected and infected C. elegans nematodes (average ± SD) receiving no 
treatment (CTRL) or a treatment with the compounds at different concentrations. The results are expressed 
as percentage survival after 24 h and 48 h of infection. *Survival of infected and treated C. elegans is significantly 
higher compared to the infected untreated controls (p < 0.05).
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were observed after 24 h between uninfected C. elegans nematodes and nematodes infected with B. cenocepacia 
J2315 which were treated with 25 μ M of 6a or 8b (96% ± 5%, 91% ± 9% and 91% ± 5% after 24 h, respectively). In 
addition, both compounds significantly increased survival of infected nematodes after 24 h and 48 h even when 
administered concentrations were as low as 1 μ M (Table 1).
Effect of 8b and 6a on HeLa cells. The toxicity of the newly synthesized compounds was tested on HeLa 
cells which were exposed to 8b and 6a at the concentrations of 10, 25, 50 and 100 μ M. Following exposure, cells 
were counted after 24 h and 48 h. Compound 8b at 100 μ M already caused approximately a 20% reduction in cell 
viability after 24 h (Fig. 6); the effect was stronger at 48 h. Significant toxicity (p < 0.05) could be observed using 
50 μ M compound concentration after 48 h (approximately 50% cell viability reduction) (Fig. 6). For both con-
centrations, microphotographs collected at 72 h confirmed cell death using either 50 and 100 μ M concentrations 
(Supplementary Fig. S6).
Concentrations as low as 25 μ M did not induce cell death (Supplementary Fig. S6), however the cells stopped 
growing between 24 h and 48 h.
On the other hand, compound 6a displayed a lower cell toxicity (Fig. 6) and significant effects (p < 0.05) on 
cell growth were observed only after 48 h treatment at a concentration of 100 μ M. Furthermore, the fact that 6a 
did not induce cell death was obvious from microphotographs after 72 h (Supplementary Fig. S6).
Discussion and Conclusions. There is a lack of new therapeutic solutions for B. cenocepacia infections, and 
targeting the QS system of this organism could be a promising approach, potentially with less pressure to select 
resistant strains32. This is particularly important as antimicrobial resistance is recognized worldwide as one of the 
major public health concerns of our century33. Different strategies can be pursued to block QS systems: the inhi-
bition of the synthesis of the signal molecule; targeting the signal molecule itself (by degradation or deactivation) 
and/or antagonizing the regulator11.
Several recent studies reported the use of molecules able to inhibit QS regulators, such as thiazolidinedione 
analogues that block the DNA binding ability of LuxR in Vibrio harveyi34 or AHLs and their precursor synthesis 
in Pseudomonas aeruginosa35. Moreover, other groups developed analogues of autoinducing peptides to inhibit 
QS receptors and attenuate virulence in Staphylococcus aureus36 and Staphylococcus epidermidis37.
In the present study we focused on a third possible target of the QS pathway, the AHL synthase CepI of 
B. cenocepacia J2315. Diketopiperazine molecules inhibit the enzymatic activity of CepI in vitro, and by doing 
so downregulate the production of virulence factors; such hypothesis was clearly confirmed regarding protease 
production. The production of siderophores is another well-recognized potential virulence factor implicated in 
the pathogenesis of B. cenocepacia infections, as demonstrated in CF clinical isolates38. An example would be 
pyochelin: this molecule plays a role in tissue injury in addition to iron acquisition, as it is an efficient catalyst for 
hydroxyl radical formation39. CepR was shown to negatively regulate its own expression as well as the siderophore 
ornibactin biosynthesis through the pvdA gene39. Lewenza and Sokol (2001)39 demonstrated that iron increases 
cepR expression, which could lead to higher levels of pvdA repression in WT strains, and that cepR mutations have 
a greater effect on pvdA expression in the presence of high iron concentrations in the culture medium. Moreover, 
iron acquisition via the siderophore ornibactin (encoded by pvdA) was confirmed to play a role in the early 
stages of B. cenocepacia colonization40. On the other hand, previous studies demonstrated that the B. cenocepacia 
H111 strain (which lacks the CciIR system) mutated in cepR, cepR2 or both show a diminished production of 
siderophores41. Moreover, in a B. cenocepacia J2315 double mutant in cepI-cciI the ornibactin synthase encoding 
gene orbI was significantly downregulated18. Treatment of B. cenocepacia J2315 with both compounds 8b and 6a 
resulted in a diminished production of siderophores, thus demonstrating their efficacy against virulence.
Diketopiperazines have been also shown to affect biofilm formation of B. cenocepacia J2315. This is in accord-
ance with our previous findings, in which biofilms formed by a mutant lacking the cepI gene were much thinner, 
Figure 6. Compound toxicity assessment. HeLa cell viability in the presence of 8b (A) and 6a (B), after 24 h 
(black bars) and 48 h (grey bars) of incubation with different compound concentrations. DMSO, cells treated 
with the highest amount of solvent. *Indicates a significant decrease in cell viability (p < 0.05).
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less densely packed and covered only parts of the surface18. Diketopiperazines were also assayed against plank-
tonic growing cells but, as expected for compounds which hit the non-essential QS pathway, they did not show 
any antimicrobial property, as demonstrated by MIC determination experiments. On the contrary, very promis-
ing results were obtained in C. elegans, where the effect of two inhibitors was clearly demonstrated in vivo, even 
at low concentrations (down to 1 μ M, after 48 h treatments). In a previous study18 we constructed mutants in 
B. cenocepacia strain J2315, in which genes encoding CepI (BCAM1870), CciI (BCAM0239a) and the BDSF syn-
thase (BCAM0581) were inactivated (either in single, double or triple mutants) and several phenotypic properties 
(including biofilm formation and virulence in C. elegans) were investigated. Interestingly, although all QS mutant 
strains displayed an impaired ability to form biofilms, this effect on biofilm formation was most pronounced 
in mutant strains lacking the cepI gene. While the WT strain formed a thick densely packed biofilm, biofilms 
formed by the cepI mutant were much thinner, less densely packed and covered only parts of the surface. Similar 
observations were made when the B. cenocepacia J2315 was treated with the compounds described in this study. 
In addition, our previous publication indicated that the pathogenicity of B. cenocepacia J2315 towards C. elegans 
nematodes was significantly impaired when QS genes were deleted in this strain. In the present study we observed 
that, in absence of treatment, the survival of infected nematodes was only of 65%, whereas their survival reached 
maximum values of 91% when they received treatment with 25 μ M of 6a or 8b, respectively; these levels of sur-
vival are similar to those of nematodes infected with a QS-deficient mutant.
Furthermore, the tests performed with HeLa cells confirmed the non-toxicity of diketopiperazines. This last 
observation is very important, because despite the fact that many QSIs have been described42 no candidates have, 
as of yet, reached clinical trials, either because of their toxicity or due to their lack of in vivo activity43,44.
Despite the lack of structural data on CepI, the high degree of sequence identity with TofI and other AHL 
homologs allowed generation of a reliable structural model of the enzyme, which enabled evaluation of the struc-
tural features critical for the catalytic activity of CepI. Docking of the newly discovered 8b inhibitor onto the 
CepI structural model consistently showed multiple candidate binding sites on the enzyme surface, distant from 
the CepI catalytic site but in regions that may have strong implications in substrate recognition and catalysis. It 
should be pointed out that, at present, the exact mechanism of action of QSIs is poorly understood45. As such the 
design of our compounds and their screening for inhibition of CepI was based on a high-throughput screening 
assay. Structural data on CepI or related AHL synthases in complex with these molecules will nevertheless be 
necessary to understand the molecular mechanism of non-competitive enzyme inhibition.
In conclusion, alternative strategies to the use of antimicrobials are emerging as favourable against bacteria 
intrinsically resistant to the classical antibiotics, as in the case of B. cenocepacia. In this respect, our data show that 
diketopiperazines are very promising therapeutic candidates.
Methods
QSI synthesis. The general procedure for the synthesis of diketopiperazine derivatives is described 
in the Supplementary Materials and Methods. Briefly, synthesis of diketopiperazines was performed using 
2′ ,5′ -dihydroxyacetophenone 1 as starting material. The first step was the benzyl protection of hydroxyl group. 
This compound was then oxidized with selenium oxide in pyridine and the resulting acid 3 was turned into 
the corresponding chloroanhydride 4 by treatment with thionyl chloride in presence of catalytic quantities of 
DMF. Aminoesters reacted with the chloroanhydride 3 in DMF and in presence of triethylamine with formation 
of the corresponding diphenoxyderivatives 5a-c. Their cyclisation to the diketopiperazines 6a-c was made in 
bomb in presence of excess of ammonia. De-protection of hydroxygroups was performed by hydrogenation in 
the presence of palladium of carbon, with high yield, and oxidation of the product followed to generate quinine 
derivatives 8a-c. Hydroquinone 7a was also refluxed with acetic acid anhydride to result in the formation of the 
corresponding 4 acetyl derivative 9 (Fig. 7).
CepI heterologous expression and purification. cepI was amplified using CepISUMOfor 
(5′ -ATGCAGACCTTCGTTCAC-3′ ) and CepISUMOrev (5′ -TCAGGCGGCGATAGCTTG-3′ ) as primers 
and B. cenocepacia J2315 genomic DNA as template. Cycling conditions were 4 min 94 °C, 30 cycles 30 s 98 °C, 
30s 50 °C, 1 min 72 °C and 10 min 72 °C. The amplified fragment was cloned into pETSUMO (Invitrogen). 
For protein expression, E. coli BL21(DE3) cells were transformed with the pET-SUMO-cepI plasmid and 
grown at 37 °C until an OD600nm of 0.6–0.8 was reached. Recombinant expression was induced with 0.5 mM 
isopropyl-β -thiogalactopyranoside (IPTG), at 25 °C O/N. Cells were harvested by centrifugation, resuspended in 
50 mM TrisHCl pH 8.0, 300 mM NaCl, 5% glycerol, 1 mM DTT (Buffer A), plus 5 mM imidazole, 1:100 Protease 
Inhibitor Cocktail (Sigma-Aldrich), 50 μ g/ml DNase and disrupted by sonication. The cell-free extract, obtained 
after 50 min centrifugation at 30,000 × g, was applied onto an HisTrap column (1 ml, GE-Healthcare), washed 
with 20 mM imidazole and the protein was eluted with 350 mM imidazole. Tag cleavage was achieved by O/N 
incubation with 0.3 mg of SUMO protease dialyzed against Buffer A, followed by a second purification with the 
HisTrap column to remove both the cleaved tag and the SUMO protease. The protein was finally concentrated and 
loaded onto a HiLoad 26/60 Superdex 200 size exclusion chromatography column (GE Healthcare), equilibrated 
in 50 mM TrisHCl pH 8.0, 150 mM NaCl, 1 mM DTT. Protein quality was checked by SDS-PAGE and its concen-
tration was evaluated by measuring its absorbance at 280 nm (ε = 26720 M−1 cm−1).
C8-ACP preparation. Octanoyl-ACP (C8-ACP), was prepared as previously reported46,47, using the Bacillus 
subtilis phosphopantetheinyl transferase (Sfp) and the E. coli acyl carrier protein (ACP), both obtained in recom-
binant form (see Supplementary Information).
1 mM ACP was incubated with 10 μ M Sfp, 10 mM octanoyl-CoA, 10 μ M MgCl2, 1 mM DTT in 100 mM 
TrisHCl pH 8.0, at 37 °C for 16 h. Sfp was precipitated with 75% saturation (NH4)2SO4 for 1 h at 4 °C, and removed 
by centrifugation. ACP was precipitated O/N at − 20 °C with two volumes of acetone. The obtained C8-ACP 
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was collected by centrifugation, dried, suspended in 25 mM TrisHCl pH 7.5, and stored at − 80 °C until use. The 
conversion of ACP was checked by conformation sensitive native PAGE (20% polyacrylamide and 0.5 M urea)48.
Enzymatic assay. Determination of the CepI enzyme activity was performed spectrophotometrically by meas-
uring holo-ACP formation with dichlorophenylindophenol (DCPIP; ε = 19100 M−1 cm−1) at 37 °C according to 
Christensen et al.19. Reaction mixtures typically contained 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid pH 7.5 (HEPES), 0.005% Nonidet P-40, 0.13 mM DCPIP, 70 μ M C8-ACP, 40 μ M S-adenosyl methionine 
(SAM), 4 μ M CepI and the reaction was started by addition of SAM after pre-incubation for 10 min.
Steady-state kinetic parameters Km and kcat were determined by assaying the enzymes in triplicate at 8 different 
substrate concentrations, and fitting the data to the Michaelis-Menten equation using Origin 8 software.
CepI inhibition was initially screened for all compounds at 100 μ M (dissolved in DMSO). For compounds 
that significantly inhibited the enzyme activity in these conditions, IC50 and Ki values were determined. To deter-
mine IC50, the enzyme activities were measured in presence of different concentrations of compounds and values 
determined with equation (1):
= ×


 +


I
A A 10 [I]
[ ] IC (1)
I[ ] [0]
50
where A[I] is the enzyme activity at inhibitor concentration [I] and A[0] is the enzyme activity without inhibitor.
Ki determination was determined using the equation (2) for noncompetitive inhibition49:
=
+ + +
α( ) ( )
v V
S K
[S]
[ ] 1 1 (2)K K
max
[I]
m
[I]
i i
Protease assay. The protease activity assay was conducted using azocasein, as previously described18. Briefly, 
B. cenocepacia J2315 was grown O/N in LB at 37 °C in the presence of increasing concentrations (1–100 μ M) of 
CepI inhibitors 6a or 8b. In order to keep the same amount of solvent added, different stock solutions of the inhib-
itors were prepared. The corresponding amount of DMSO was used as control. The OD at 600 nm was determined 
and 250 μ l of cell-free supernatant were incubated with 250 μ l azocasein (5 mg/ml in 100 mM TrisHCl pH 8.0) at 
37 °C for 1 h. This reaction was blocked by adding 50 μ l 10% trichloroacetic acid and samples were centrifuged. 
The supernatant was transferred to 350 μ l NaOH (525 mM) and the optical density at 420 nm was measured.
Siderophore production assay. Siderophore activity present in the culture was tested using Chromeazurol 
S (CAS) agar plates30. B. cenocepacia J2315 was grown O/N in LB at 37 °C in the presence of increasing concen-
trations (1–100 μ M) of the CepI inhibitors 6a and 8b and 2 μ l of each culture were spotted on CAS agar plates and 
incubated for 48 h at 37 °C.
Figure 7. Reagents and conditions. (a) PhCH2Cl, EtOH, K2CO3, reflux, 4 h, 77%; (b) SeO2, pyridine, 100 °C, 
3 h, 81%; (c) SOCl2, CCl4, DMF, reflux, 3 h; (d) H2NCHRCOOMe, Et3N, DMF, 48 h; (e) NH3/EtOH, 48 h, 
150 °C; (f) H2, 10% Pd/C, DMF; (g) HClO4, H2SO4, HNO3, AcOH, 3 h; (h) Ac2O, reflux, 6 h, 69%.
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Biofilm assay. B. cenocepacia J2315 was grown overnight in Mueller Hinton (MH), centrifuged and resus-
pended in MH to an OD590 nm of 0.2. Ninety-nine μ l of the bacterial suspension were transferred to the wells of 
black flat-bottom 96-well microtiter plate with a glass bottom (TPP). One μ l control solution (i.e. solvent without 
active molecule) was added to the control wells (untreated) and 1 μ l of 6a or 8b solution (concentrated 100 times) 
was added to the test wells (treated). Bacteria were allowed to adhere and grow without agitation for 4 h at 37 °C. 
After 4 h, plates were emptied and washed with sterile physiological saline (PS). Following this wash step, all wells 
were filled with 99 μ l MH and 1 μ l of either the solvent solution or of a solution of 6a or 8b, the plate was then 
incubated for 20 h at 37 °C. After 24 h biofilm formation, medium was removed, biofilms were washed with 100 μ l 
PS and 100 μ l of a staining solution (containing 3 μ l of SYTO9 and 3 μ l of propidium iodide in 1 ml of PS; Life 
technologies) were added. These plates were incubated in the dark for 15 min at room temperature and the bio-
film was visualized with a Nikon C1 confocal laser scanning microscope (Nikon Benelux, Brussels, Belgium) as 
previously described50. Tests were performed on at least three wells for each condition and representative images 
are shown.
Virulence assay in Caenorhabditis elegans. C. elegans N2 (glp-4; sek-1) was propagated under standard 
conditions, synchronized by hypochlorite bleaching, and cultured on nematode growth medium using E. coli 
OP50 as a food source, as described previously51,52. The C. elegans survival assay was carried out as described 
previously31. In brief, synchronized worms (L4 stage) were suspended in a medium containing 95% M9 buffer, 
5% brain heart infusion broth (Oxoid), and 10 μ g of cholesterol (Sigma-Aldrich) per ml. Fifty μ l of this suspension 
of nematodes were transferred to the wells of a 96-well microtiter plate where 49 μ l of medium were added to the 
uninfected control wells. An overnight bacterial culture was centrifuged, resuspended in the assay medium, and 
standardized to 109 CFU/ml. Aliquots of 49 μ l of this standardized suspension were added to the wells. Next, 1 μ l 
solvent control or 1 μ l of a 100-times concentrated solution of 6a or 8b was added to the test wells. Subsequently 
the plates were incubated at 25 °C for up to 2 days. The fraction of dead worms was determined by counting the 
number of dead worms and the total number of worms in each well, using an Evos FL auto Microscope (Life 
technologies). The compounds were tested at least six times in each assay and each assay was repeated at least 
two times (n ≥ 12). At least 25 C. elegans nematodes were used for in each well (n ≥ 300 nematodes/condition).
Mammalian cell viability assay. Human cervical carcinoma-derived HeLa cells were maintained in rou-
tine culture with weekly splitting. Cells were cultured in DMEM medium supplemented with fetal bovine serum 
(10%), L-glutamine (1%), penicillin (100 U/ml), streptomycin (100 μ g/ml) and maintained at 37 °C in 5% CO2 
atmosphere. All reagents were purchased from Life Technologies. Twenty-four hours before drug treatment, cells 
were trypsinized, resuspended in medium and counted on a Z2 Beckman Coulter counter (Beckman Coulter) in 
order to obtain a confluent 12-wells plate. Different drug concentrations were tested as reported in each exper-
iment and cell counting was performed respectively at 24 h and 48 h for each concentration. Cell viability data 
were derived from two independent experiments and were normalized to NT sample at 24 h. NT samples were 
subjected only to DMSO solvent. Microphotographs were obtained through an inverted microscope (Nikon) 
equipped with phase contrast and dark field illumination.
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